DOCSLIB.ORG

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ranitidine Hydrochloride

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ranitidine Hydrochloride COMMENTARY Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ranitidine Hydrochloride H. KORTEJA¨ RVI,1 M. YLIPERTTULA,1 J.B. DRESSMAN,2 H.E. JUNGINGER,3 K.K. MIDHA,4 V.P. SHAH,5 D.M. BARENDS6 1Orion Pharma, Research and Development, Espoo, Finland 2Institut fu¨r Pharmazeutische Technologie, Johann Wolfgang Goethe-Universita¨t, Frankfurt am Main, Germany 3Leiden/Amsterdam Center for Drug Research, Leiden University, Division of Pharmaceutical Technology, Leiden, The Netherlands 4University of Saskatchewan, Saskatoon, Canada 5U.S. Food and Drug Administration, Center of Drug Evaluation and Research, Rockville, Maryland 6RIVM, National Institute for Public Health and the Environment, P.O. Box 1, 3720 BA Bilthoven, The Netherlands Received 8 December 2004; revised 1 April 2005; accepted 7 April 2005 Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/jps.20392 ABSTRACT: Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate release (IR) solid oral dosage forms containing ranitidine hydrochloride are reviewed. According to the current Biopharmaceutics Classification System (BCS), ranitidine hydrochloride should be as- signed to Class III. However, based on its therapeutic and therapeutic index, pharma- cokinetic properties and data related to the possibility of excipient interactions, a biowaiver can be recommended for IR solid oral dosage forms that are rapidly dissolving and contain only those excipients as reported in this study. ß 2005 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 94:1617–1625, 2005 Keywords: absorption; Biopharmaceutics Classification System (BCS); ranitidine; permeability; solubility INTRODUCTION dosage forms. The purpose and scope of these monographs were discussed previously.1 Briefly, A monograph based on literature data is pre- the aims of the present study were to evaluate all sented on ranitidine hydrochloride with respect to pertinent data available from literature sources to its biopharmaceutical properties and the risk of assess the appropriateness of such a biowaiver waiving in vivo bioequivalence testing for the from the biopharmaceutical point of view and also approval of new and reformulated IR solid oral from the perspective of public health risks. This study reflects the scientific opinion of the authors and not the policies of regulating agencies. EXPERIMENTAL Correspondence to: Dirk M. Barends (Telephone: þ31 30 2744209; Fax: þ31 30 2744462; E-mail: [email protected]) The databases Caplus, Ipa, and Medline were Journal of Pharmaceutical Sciences, Vol. 94, 1617–1625 (2005) ß 2005 Wiley-Liss, Inc. and the American Pharmacists Association utilized to search using the keyword permeability JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 94, NO. 8, AUGUST 2005 1617 1618 KORTEJA¨ RVI ET AL. and Caplus and Ipa using the keywords dissolu- dine hydrochloride with different polymorphic tion, solubility, and degradation. The pharmaco- forms were reported to be bioequivalent.3 kinetic data search was initiated from the Martindale and the Drug Information Fulltext, followed by reviewing the references cited. Partition Coefficient Information with regard to the double-peak LogP (water/n-octanol) was reported to be 0.2.4 phenomenon, site-dependent absorption, first- This value is likely for the ionized form, i.e., logD. pass metabolism, enterohepatic recycling, and LogP (for the neutral molecule) was calculated to bioequivalence studies were reviewed from the be 1.28.5 cited literature obtained from Medline, using the keyword pharmacokinetics. Only literature writ- ten in English and German was included and the pKa searches were not limited to a certain time period. The two pK values reported 8.2 and 2.7 4 are in As the solubility data from literature did not cover a agreement with the values of 8.4 and 3.5, res- the entire physiological pH range, these were pectively, calculated with a structure-fragment- obtained experimentally at Orion Pharma. Tri- based approach.5 plicate determinations were carried out in which the solute was shaken with buffers pH 1, 3, 5, and 7.4 at room temperature for 3 h and the obtain- Indication ed solutions analyzed by high performance liquid chromatography. Ranitidine is a histamine H2-antagonist used in the treatment of gastric and duodenal ulceration with or without Helicobacter pylori infection and for gastro-oesophageal reflux disease.2 Ranitidine RESULTS inhibits gastric acid secretion, which is stimu- lated by pentagastrin, histamine, and normal General Characteristics meals.6 The incidence of adverse drug reactions with H -receptor antagonists are low (<3%) and The INN and World Health Organization (WHO) 2 are usually minor in nature.7 For Zollinger– name for ranitidine, is N-[2-[[[-5-[(dimethylamino) Ellison syndrome doses up to 900 mg daily have methyl]-2-furanyl]methyl]thio]ethyl]-N0-methyl-2- been used without troublesome side effects.6 nitro-1,1-ethenediamine. The WHO recommended dose for ranitidine tablets is 150 mg ranitidine base, given as the hydrochloride salt.8 Strengths currently having a Structure marketing authorization (MA) in Germany (DE)9, See Figure 1. Finland (FI),10 and The Netherlands (NL)11 are the equivalents of 75, 150, and 300 mg ranitidine base. Salt, Esters, Polymorphs Most preparation contain the hydrochloride 2 and Solubility this monograph covers only that salt of ranitidine. The solubility of ranitidine hydrochloride in water Ranitidine hydrochloride exhibits polymorphism.2 is 660 mg/mL and it is reported to be freely soluble Immediate-release (IR) tablets containing raniti- in water.2 The solubility in the pH range 1–7.4 was experimentally found to be over 550 mg/mL. As the highest strength is 300 mg, the dose: solubility ratio is less than 0.55 mL, far below the critical value of 250 mL.12,13 However, these data were obtained at room temperature and the cri- teria of ‘‘highly soluble’’ according to FDA and EMEA Guidelines are defined at 378C.12,13 But, supposing that the solubility will be higher at 378C than at room temperature, it is reason- Figure 1. Structure of ranitidine. able safe to classify ranitidine hydrochloride as a JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 94, NO. 8, AUGUST 2005 BIOWAIVER MONOGRAPH FOR RANITIDINE HYDROCHLORIDE 1619 ‘‘highly soluble’’ active pharmaceutical ingredient and discussed earlier as these observations can be (API). explained on the basis that tight junctions in the intestinal cell tissues are more permeable than the tight junctions in the Caco-2 monolayers.1 Pharmacokinetics Despite these differences, both permeability tech- Absorption niques demonstrate that the permeability is low. Indeed, ranitidine is recommended as a low per- The oral bioavailability (BA) of ranitidine is 50%– meability internal standard in the FDA guideline 60%. The drug is reported to be rapidly absorbed for Caco-2 permeability studies.12 The Caco-2 per- when administered via the oral route14–18 and meability increases when calcium concentration is absorption after oral administration is linear.19 decreased in the test medium,26 which can be ex- A first peak in plasma concentrations is reached plained on the basis that low calcium concentra- within 0.5–1.5 h and a second peak is observed tions cause opening of the tight junctions of the within 3–4 h after single doses.20,21 The reasons paracellular route or change the membrane integ- for this double-peak phenomenon are unclear. rity by disturbing the phospholipid bilayers. Thus, This is likely not due to biliary excretion, as the main absorption mechanism of ranitidine is biliary excretion is only 0.4% after oral adminis- paracellular passive diffusion. In vitro and non- tration.22 Variations in gastric emptying may also clinical studies have suggested that ranitidine is a not be a satisfactory explanation, since when substrate for P-gp.28,30,32 But it is likely that high ranitidine was administered as a solution directly doses of this highly soluble drug, formulated in to the jejunum, double-peaks were observed even rapidly dissolving tablets, will cause saturation of more often than after administration to the the P-gp efflux protein. stomach.23 In any case, this double-peak pheno- menon is not relevant for biowaiver decisions, as Distribution there is no indication that it is formulation- dependent. The apparent volume of the distribution for ter- The BA of ranitidine is significantly lower when minal phase is about 1.16–1.87 L/kg.14,15,21,25,33 administered as a solution directly to the colon Ranitidine has a low protein binding of about instead of stomach, jejunum, or ileum.23,24 Since 15%.15 the tight junctions in the colon are considerably less permeable than those in the small intestine, it Metabolism and Excretion can be hypothesized that ranitidine is absorbed by The urinary excretion of unchanged ranitidine a paracellular mechanism, with the main absorp- following intravenous (i.v.) administration is 70%– tion site in the small intestine. Food in general has 80%,4,17,18,21,25 whereas the renal excretion of no effect on the rate and extent of absorption.25 unchanged drug after oral dosing is 25%– 30%.4,15,17,21 Less than 10% of the dose is metabo- Permeability lized and excreted via the urinary route after Results of permeability measurements are shown either i.v. or oral dosing.15,17 Of orally adminis- in Table 1. tered ranitidine, 26% is excreted with the feces.10 The results of the Caco-2 studies and the human Half-life of elimination phase is 1.7–2.1 h after i.v. intestinal permeability technique show large dif- dose.14,15,19,21 There are no reports that ranitidine ferences. These differences have been reported follows non-linear pharmacokinetics. Table 1. Permeability of Ranitidine Concentration Used (mM) Method Papp/Peff (Â10À7 cm/s) Reference 0.000142–14.25 Caco-2 1.03 26 0.1–5 Caco-2 18–7.5 27 0.005–5 Caco-2 20–12 28 2.56 Caco-2 3.1a 29 — Caco-2 12.4 30 0.5 Intestinal perfusion 270 31 aFurosemide, atenolol, and propranolol were used as reference compounds.
Load more

Recommended publications
  • ZANTAC® 150 (Ranitidine Hydrochloride) Tablets, USP
    PRESCRIBING INFORMATION ZANTAC® 150 (ranitidine hydrochloride) Tablets, USP ZANTAC® 300 (ranitidine hydrochloride) Tablets, USP ZANTAC® 25 (ranitidine hydrochloride effervescent) ® EFFERdose Tablets ® ZANTAC (ranitidine hydrochloride) Syrup, USP DESCRIPTION The active ingredient in ZANTAC 150 Tablets, ZANTAC 300 Tablets, ZANTAC 25 EFFERdose Tablets, and ZANTAC Syrup is ranitidine hydrochloride (HCl), USP, a histamine H2-receptor antagonist. Chemically it is N[2-[[[5-[(dimethylamino)methyl]-2­ furanyl]methyl]thio]ethyl]-N′-methyl-2-nitro-1,1-ethenediamine, HCl. It has the following structure: The empirical formula is C13H22N4O3S•HCl, representing a molecular weight of 350.87. Ranitidine HCl is a white to pale yellow, granular substance that is soluble in water. It has a slightly bitter taste and sulfurlike odor. Each ZANTAC 150 Tablet for oral administration contains 168 mg of ranitidine HCl equivalent to 150 mg of ranitidine. Each tablet also contains the inactive ingredients FD&C Yellow No. 6 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, titanium dioxide, triacetin, and yellow iron oxide. Each ZANTAC 300 Tablet for oral administration contains 336 mg of ranitidine HCl equivalent to 300 mg of ranitidine. Each tablet also contains the inactive ingredients croscarmellose sodium, D&C Yellow No. 10 Aluminum Lake, hypromellose, magnesium stearate, microcrystalline cellulose, titanium dioxide, and triacetin. 1 ZANTAC 25 EFFERdose Tablets for oral administration is an effervescent formulation of ranitidine that must be dissolved in water before use. Each individual tablet contains 28 mg of ranitidine HCl equivalent to 25 mg of ranitidine and the following inactive ingredients: aspartame, monosodium citrate anhydrous, povidone, and sodium bicarbonate. Each tablet also contains sodium benzoate.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Receptor Antagonist (H RA) Shortages | May 25, 2020 2 2 2 GERD4,5 • Take This Opportunity to Determine If Continued Treatment Is Necessary
    H2-receptor antagonist (H2RA) Shortages Background . 2 H2RA Alternatives . 2 Therapeutic Alternatives . 2 Adults . 2 GERD . 3 PUD . 3 Pediatrics . 3 GERD . 3 PUD . 4 Tables Table 1: Health Canada–Approved Indications of H2RAs . 2 Table 2: Oral Adult Doses of H2RAs and PPIs for GERD . 4 Table 3: Oral Adult Doses of H2RAs and PPIs for PUD . 5 Table 4: Oral Pediatric Doses of H2RAs and PPIs for GERD . 6 Table 5: Oral Pediatric Doses of H2RAs and PPIs for PUD . 7 References . 8 H2-receptor antagonist (H2RA) Shortages | May 25, 2020 1 H2-receptor antagonist (H2RA) Shortages BACKGROUND Health Canada recalls1 and manufacturer supply disruptions may be causing shortages of commonly used acid-reducing medications called histamine H2-receptor antagonists (H2RAs) . H2RAs include cimetidine, famotidine, nizatidine and ranitidine . 2 There are several Health Canada–approved indications of H2RAs (see Table 1); this document addresses the most common: gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD) . 2 TABLE 1: HEALTH CANADA–APPROVED INDICATIONS OF H2RAs H -Receptor Antagonists (H RAs) Health Canada–Approved Indications 2 2 Cimetidine Famotidine Nizatidine Ranitidine Duodenal ulcer, treatment ü ü ü ü Duodenal ulcer, prophylaxis — ü ü ü Benign gastric ulcer, treatment ü ü ü ü Gastric ulcer, prophylaxis — — — ü GERD, treatment ü ü ü ü GERD, maintenance of remission — ü — — Gastric hypersecretion,* treatment ü ü — ü Self-medication of acid indigestion, treatment and prophylaxis — ü† — ü† Acid aspiration syndrome, prophylaxis — — — ü Hemorrhage from stress ulceration or recurrent bleeding, — — — ü prophylaxis ü = Health Canada–approved indication; GERD = gastroesophageal reflux disease *For example, Zollinger-Ellison syndrome .
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • IHS National Pharmacy & Therapeutics Committee National
    IHS National Pharmacy & Therapeutics Committee National Core Formulary; Last Updated: 09/23/2021 **Note: Medications in GREY indicate removed items.** Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief (if Notes / Similar NCF Active? available) Miscellaneous Medications Acetaminophen Analgesic, Miscellaneous Yes Albuterol nebulized solution Beta2 Agonist Yes Albuterol, metered dose inhaler Beta2 Agonist NPTC Meeting Update *Any product* Yes (MDI) (Nov 2017) Alendronate Bisphosphonate Derivative Osteoporosis (2016) Yes Allopurinol Antigout Agent; Xanthine Oxidase Inhibitor Gout (2016) Yes Alogliptin Antidiabetic Agent, Dipeptidyl Peptidase 4 (DPP-4) Inhibitor DPP-IV Inhibitors (2019) Yes Anastrozole Antineoplastic Agent, Aromatase Inhibitor Yes Aspirin Antiplatelet Agent; Nonsteroidal Anti-Inflammatory Drug; Salicylate Yes Azithromycin Antibiotic, Macrolide STIs - PART 1 (2021) Yes Calcium Electrolyte supplement *Any formulation* Yes Carbidopa-Levodopa (immediate Anti-Parkinson Agent; Decarboxylase Inhibitor-Dopamine Precursor Parkinson's Disease Yes release) (2019) Clindamycin, topical ===REMOVED from NCF=== (See Benzoyl Peroxide AND Removed January No Clindamycin, topical combination) 2020 Corticosteroid, intranasal Intranasal Corticosteroid *Any product* Yes Cyanocobalamin (Vitamin B12), Vitamin, Water Soluble Hematologic Supplements Yes oral (2016) Printed on 09/25/2021 Page 1 of 18 National Core Formulary; Last Updated: 09/23/2021 Generic Medication Name Pharmacological Category (up-to-date) Formulary Brief
    [Show full text]
  • Wednesday, July 10, 2019 4:00Pm
    Wednesday, July 10, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – July 10, 2019 DATE: July 3, 2019 NOTE: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the July meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – Appendix B Action Item – Vote to Prior Authorize Jornay PM™ [Methylphenidate Extended-Release (ER) Capsule], Evekeo ODT™ [Amphetamine Orally Disintegrating Tablet (ODT)], Adhansia XR™ (Methylphenidate ER Capsule), and Sunosi™ (Solriamfetol Tablet) – Appendix C Action Item – Vote to Prior Authorize Balversa™ (Erdafitinib) – Appendix D Action Item – Vote to Prior Authorize Annovera™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System), Bijuva™ (Estradiol/Progesterone Capsule), Cequa™ (Cyclosporine 0.09% Ophthalmic Solution), Corlanor® (Ivabradine Oral Solution), Crotan™ (Crotamiton 10% Lotion), Gloperba® (Colchicine Oral Solution), Glycate® (Glycopyrrolate Tablet), Khapzory™ (Levoleucovorin Injection), Qmiiz™ ODT [Meloxicam Orally Disintegrating Tablet (ODT)], Seconal Sodium™ (Secobarbital
    [Show full text]
  • CLINICAL REVIEW(S) Clinical Review Michael C
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210655Orig1s000 CLINICAL REVIEW(S) Clinical Review Michael C. Davis, MD, PhD and Qi Chen, MD, MPH (Safety Review) NDA 210655 Perseris (RBP-7000 risperidone-ATRIGEL) CLINICAL REVIEW Application Type Initial 505(b)(2) New Drug Application (NDA) Application Number(s) 210655 Priority or Standard Standard Submit Date(s) September 28, 2017 Received Date(s) September 28, 2017 PDUFA Goal Date July 28, 2018 Division/Office Division of Psychiatry Products/Office of Drug Evaluation I Reviewer Name(s) Michael C. Davis, MD, PhD; Qi Chen, MD, MPH (Safety Review) Review Completion Date June 22, 2018 Established/Proper Name RBP-7000 (risperidone-ATRIGEL) (Proposed) Trade Name Perseris Applicant Indivior Dosage Form(s) Injectable Suspension Applicant Proposed Dosing 90 mg or 120 mg subcutaneous injection monthly Regimen(s) Applicant Proposed Schizophrenia/Adults Indication(s)/Population(s) Recommendation on Approve Regulatory Action Recommended N/A Indication(s)/Population(s) (if applicable) CDER Clinical Review Template 1 Version date: September 6, 2017 for all NDAs and BLAs Reference ID: 4288016 Clinical Review Michael C. Davis, MD, PhD and Qi Chen, MD, MPH (Safety Review) NDA 210655 Perseris (RBP-7000 risperidone-ATRIGEL) Table of Contents Glossary ........................................................................................................................................... 9 1. Executive Summary ..............................................................................................................
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • Effervescent H2 Blocker Formulation
    Europaisches Patentamt European Patent Office © Publication number: 0 492 247 A1 Office europeen des brevets EUROPEAN PATENT APPLICATION © Application number: 91121064.9 © int. CIA A61K 31/34, A61K 9/00 @ Date of filing: 09.12.91 ® Priority: 21.12.90 US 633230 @ Inventor: Paulos, Manley A. 15626 Cold Springs Court @ Date of publication of application: Indiana 01.07.92 Bulletin 92/27 Granger, 46530(US) © Designated Contracting States: AT BE CH DE DK ES FR GB GR IT LI LU NL SE © Representative: Danner, Klaus, Dr. et al c/o Bayer AG Konzernverwaltung RP © Applicant: MILES INC. 1127 Myrtle Street Patentabteilung ElkhartJN 4651 5(US) W-5090 Leverkusen 1 Bayerwerk(DE) (§v Effervescent H2 blocker formulation. © An aqueous solution of H2 Blocker and an effervescent delivery system. Immediate and continuous relief is provided for from about 1 to about 3 hours, even when the administered composition contains less than about 25 percent of the dosage of H2 Blocker prescribed for active duodenal ulcer. 7.0 r 0,3mg/kg+0,0mEq 7.0 0,3 mg/kg + 32mEq 0,0mg/kg+0,0mEq 0,0mg/kg +0,0mE q 6.0 6,0 5,0 5,0 Xa. *4.0 :4.0 ^3.0 :3,0 1^2,0 h is 2,0 1.0 h 1.0 ■ 0.0 _i i ■ ■ 0.0 CM -60 0 60 120 180 240 -60 0 60 120 180 240 Time After Dosing (Minutes) CM Time After Dosing (Minutes) Oi FIG.1Q FIG.Id Rank Xerox (UK) Business Services EP 0 492 247 A1 Background of the Invention Histamine H2 receptor blocking agents (referred to herein as H2 Blockers) are a class of drugs which act as antagonists of the histamine H2 receptor.
    [Show full text]
  • Appendix 1 BNF Codes of Drugs Lists Used to Define Exposure Groups
    Appendix 1 BNF Codes of drugs lists used to define exposure groups. Anticholinergic antipsychotics d411. Chlorpromazine d412. Chlorpromazine d413. Chlorpromazine d414. Chlorpromazine d415. Chlorpromazine d41a. Chlorpromazine d41b. Chlorpromazine d41c. Chlorpromazine d41d. Chlorpromazine d4b1. Perphenazine d4e1. PROMAZINE d4ex. PROMAZINE d4g.. Thioridazine d4g1. Thioridazine d4g2. Thioridazine d4g3. Thioridazine d4g5. Thioridazine d4g7. Thioridazine d4gp. Thioridazine d4gt. Thioridazine d4gu. Thioridazine d4gv. Thioridazine d4gw. Thioridazine d4gz. Thioridazine d4h.. Trifluoperazine d4h1. Trifluoperazine d4h2. Trifluoperazine d4h3. Trifluoperazine d4h4. Trifluoperazine d4hs. Trifluoperazine d4ht. Trifluoperazine d4hu. Trifluoperazine d4hx. Trifluoperazine d4l2. CLOZAPINE d4r1. OLANZAPINE d4r3. OLANZAPINE d4r7. OLANZAPINE d4s1. QUETIAPINE d4s2. QUETIAPINE d4s3. QUETIAPINE d4s5. QUETIAPINE d4ss. QUETIAPINE d4sx. QUETIAPINE Tricyclic antidepressants d7... d71.. Amitriptyline d711. Amitriptyline d712. Amitriptyline d713. Amitriptyline d719. Amitriptyline d71a. Amitriptyline d71b. Amitriptyline d71c. Amitriptyline d71d. Amitriptyline d71e. Amitriptyline d71f. Amitriptyline d71u. Amitriptyline d71v. Amitriptyline d71w. Amitriptyline d71y. Amitriptyline d71z. Amitriptyline d73.. Clomipramine d731. Clomipramine d732. Clomipramine d733. Clomipramine d736. Clomipramine d73s. Clomipramine d73t. Clomipramine d73u. Clomipramine d73v. Clomipramine d73w. Clomipramine d73z. Clomipramine d75.. DOSULEPIN d751. DOSULEPIN d752. DOSULEPIN d755. DOSULEPIN d756.
    [Show full text]
  • Carvedilol Suppresses Intractable Hiccups
    J Am Board Fam Med: first published as 10.3122/jabfm.19.4.418 on 29 June 2006. Downloaded from BRIEF REPORTS Carvedilol Suppresses Intractable Hiccups Danielle Stueber, MD, and Conrad M. Swartz, PhD, MD Carvedilol (6.25 mg, 4 times daily) relieved 2 years of constant hiccupping, marked tardive dyskinesia, compulsive self-induced vomiting, and feelings of hopelessness and low mood in a 59-year-old African- American man. He previously failed trials of ranitidine, chlorpromazine, promethazine, tegaserod, on- dansetron, metoclopramide, pantoprazole, pyloric injections of botulinum toxin A, and a vagal nerve stimulator. At a 5-month follow-up, improvement was maintained; there had been several instances of rapid relapse on carvedilol discontinuation. (J Am Board Fam Med 2006;19:418–21.) This report describes a case of persistent and in- Case Reports tractable postoperative hiccups of 2 years duration The patient was a 59-year-old African-American that responded to carvedilol after nonresponse to man, admitted to the hospital for nausea, frequent typical therapies. The chronic singultus was one of coffee ground hematemesis, and associated anemia, several concurrent pathologic conditions, including besides unrelenting hiccups. Hiccups began episod- self-induced vomiting, tardive dyskinesia secondary ically 10 years prior. These episodes were initially to metoclopramide use, and depressed mood. relieved by self-induced vomiting and attributed to Although major causes of hiccups are associated diabetic gastroparesis. The patient underwent sev- with gastrointestinal ailments, persistent hiccups eral upper endoscopic examinations, which re- can be induced by tumors, chemotherapy, diabetes, vealed gastric erosions, a 3-cm hiatal hernia, and a uremia, or brain disease.
    [Show full text]
  • Early Effects of Oral Administration of Omeprazole and Roxatidine on Intragastric Ph
    Iida et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2012 13(1):29-34 29 Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) ISSN 1673-1581 (Print); ISSN 1862-1783 (Online) www.zju.edu.cn/jzus; www.springerlink.com E-mail: [email protected] Early effects of oral administration of omeprazole and roxatidine on intragastric pH Hiroshi IIDA1, Shingo KATO1, Yusuke SEKINO1, Eiji SAKAI1, Takashi UCHIYAMA1, Hiroki ENDO1, Kunihiro HOSONO1, Yasunari SAKAMOTO1, Koji FUJITA1, Masato YONEDA1, Tomoko KOIDE1, Hirokazu TAKAHASHI1, Chikako TOKORO1, Ayumu GOTO1, Yasunobu ABE1, Noritoshi KOBAYASHI1, Kensuke KUBOTA1, Eiji GOTOH2, Shin MAEDA1, Atsushi NAKAJIMA1, Masahiko INAMORI†‡1,3 (1Gastroenterology Division, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (2Department of Medical Education, Yokohama City University School of Medicine, Yokohama 236-0004, Japan) (3Office of Postgraduate Medical Education, Yokohama City University Hospital, Yokohama 236-0004, Japan) †E-mail: [email protected] Received Mar. 14, 2011; Revision accepted Aug. 30, 2011; Crosschecked Dec. 2, 2011 Abstract: Objective: The ideal medication for the treatment of acid-related diseases, e.g., peptic ulcers, stress- related gastric bleeding, functional dyspepsia, and gastroesophageal reflux disease, should have a rapid onset of action to promote hemostasis and relieve the symptoms. The aim of our study was to investigate the inhibitory effects on gastric acid secretion of a single oral administration of a proton pump inhibitor, omeprazole 20 mg, and an H2-receptor antagonist, roxatidine 75 mg. Methods: Ten Helicobacter pylori-negative male subjects participated in this randomized, two-way crossover study. Intragastric pH was monitored continuously for 6 h after single oral admini- stration of omeprazole 20 mg and roxatidine 75 mg.
    [Show full text]